This is a genetic condition that increases the risk of certain cancers, especially colon cancer. It also increases the risk of other cancers like ovarian cancer. It's inherited, meaning you get it from your parents.
Every report comes from a Lived member, sent anonymously.
Have you had Hysterectomy for Lynch Syndrome II?
Lynch syndrome II is an older name for Lynch syndrome, an inherited condition that raises the risk of colorectal cancer and several other cancers. The label was used for families in which cancers outside the bowel, most often of the lining of the uterus (endometrial cancer) or the ovaries, appeared alongside colorectal cancer. Today doctors define Lynch syndrome by the inherited gene change itself rather than by which cancers a family has had, so a person described as having Lynch syndrome II receives the same care as anyone with Lynch syndrome. Lynch syndrome does not cause symptoms on its own. What it changes is cancer risk: besides the colon, rectum, uterus and ovaries, it raises the risk of cancers of the stomach, small intestine, urinary tract, bile ducts, brain and skin. When cancer does develop, it often appears in a person's 40s or 50s, younger than usual. Not everyone with Lynch syndrome develops cancer. Another long-used name is hereditary nonpolyposis colorectal cancer (HNPCC). "Nonpolyposis" separates it from inherited conditions that cause hundreds of bowel polyps; people with Lynch syndrome can develop polyps at a younger age, but not in greater numbers. When Lynch syndrome also produces certain oil-gland (sebaceous) skin tumors, it has been called Muir-Torre syndrome, which is now seen as part of the same condition.
Lynch syndrome is caused by an inherited change in one of five genes: MLH1, MSH2, MSH6, PMS2 or EPCAM. The first four are mismatch repair genes, which fix the small copying errors that occur each time a cell divides its DNA. The EPCAM change works by switching off the neighboring MSH2 gene. When this repair system fails in a cell, errors build up, and that accumulation can lead to cancer. In the United States, an estimated 1 in 279 people carries a Lynch syndrome gene change, and many do not know it. One altered copy of the gene is enough to raise cancer risk. Each parent, brother, sister or child of someone with Lynch syndrome has up to a 50% chance of carrying the same change. Risk is not the same for every gene: MLH1 and MSH2 changes generally carry a higher lifetime cancer risk than MSH6 and PMS2 changes, which is why care plans are tailored to the specific gene. Women face a higher overall risk than men because of the added endometrial and ovarian cancer risk. Daily habits do not cause Lynch syndrome, but they can shift risk within it. Guidelines advise carriers that smoking, obesity and alcohol raise colorectal cancer risk and that physical activity lowers it, although the evidence for these effects in Lynch syndrome specifically is limited.
Lynch syndrome is confirmed with a genetic test that finds a disease-causing change in one of the five genes. People usually reach that test by one of three routes. The first is through a cancer diagnosis. Guidelines recommend that every colorectal and endometrial cancer be checked for faulty mismatch repair, either with a stain that shows whether the repair proteins are present in the tumor (immunohistochemistry) or a test for microsatellite instability (MSI), a pattern of copying errors that builds up when repair fails. An abnormal result does not prove Lynch syndrome, because the same pattern can arise in the tumor alone, but it prompts further testing and usually a blood test for an inherited change. The second is family history: several relatives with colorectal, endometrial or related cancers, especially at young ages. Family history alone misses many people, so it is a reason to be tested rather than a way to diagnose. The third is cascade testing, in which relatives of someone with a known gene change are tested for that specific change. Genetic counseling before testing helps people understand what a result would mean for them and their family. In the United States, the Genetic Information Nondiscrimination Act (GINA) protects against genetic discrimination by health insurers and most employers, but it does not cover life, long-term care or disability insurance. Occasionally a tumor shows faulty repair but no inherited change is found (sometimes called Lynch-like syndrome); care is then guided by personal and family history.
Nothing removes the inherited risk itself, so care focuses on finding cancer early or preventing it, with a plan matched to the specific gene. Colonoscopy is the core of that plan. It lets doctors find and remove polyps before they turn into cancer, and regular surveillance lowers both the number of colorectal cancers and deaths from them. Schedules differ by gene and by guideline. A US guideline recommends colonoscopy at least every 2 years starting between ages 20 and 25, with yearly exams considered for confirmed carriers. A European guideline recommends every 2 to 3 years starting at 25 for MLH1 and MSH2 carriers and at 35 for MSH6 and PMS2 carriers, with longer intervals possible for PMS2. Some guidelines also suggest a baseline upper endoscopy (a camera exam of the stomach and upper small intestine) around age 30 to 35, including a test for the stomach bacterium Helicobacter pylori. For women, endometrial and ovarian cancer can be prevented by surgery to remove the uterus, ovaries and fallopian tubes (hysterectomy with bilateral salpingo-oophorectomy) once childbearing is complete. For carriers of MLH1, MSH2 or MSH6 changes, it is typically offered from around age 35 to 45. Removing the ovaries before natural menopause brings on menopause, with hot flashes, vaginal dryness and reduced sexual function, so estrogen replacement is usually offered until about age 51. Until surgery, routine screening tests have not been shown to improve outcomes for these cancers; prompt investigation of symptoms matters more. The combined birth control pill lowers endometrial and ovarian cancer risk and is a reasonable choice for women who want contraception. Daily aspirin may reduce the risk of colorectal and other Lynch-related cancers. A European guideline advises carriers of this likely benefit at a dose of at least 75 to 100 mg, while an earlier US guideline judged the evidence not yet strong enough for routine use. Because aspirin can cause serious stomach bleeding, the decision should be made with a clinician. If cancer develops, it is treated much like the same cancer in anyone else, with two differences. Surgeons may remove more of the colon for MLH1 or MSH2 carriers to lower the chance of a second colon cancer. And because Lynch-related tumors often have faulty mismatch repair, they tend to respond to immunotherapy drugs called checkpoint inhibitors, such as pembrolizumab (Keytruda), which is approved for advanced colorectal cancer with this tumor profile.
For most people, living with Lynch syndrome means a long-term schedule of check-ups rather than an illness. Colonoscopies every few years, and for women a decision about risk-reducing surgery in midlife, become a regular part of adult life. The point of that schedule is to find polyps and early cancers while they are easiest to treat, and many people with Lynch syndrome never develop cancer at all. The diagnosis also reaches beyond one person. Sharing a result with parents, siblings and adult children gives them the chance to be tested and, if they carry the change, to start surveillance. Testing children is usually deferred until adulthood, because care does not change before then, except in families where cancers have appeared unusually young. Family planning can be part of the picture. Because risk-reducing surgery ends fertility, some people think about the timing of pregnancy earlier than they otherwise would. People who want to avoid passing on the gene change can ask about testing embryos during in vitro fertilization (preimplantation genetic testing).
Ask about genetic counseling if a close relative has been found to carry a Lynch syndrome gene change, if several relatives have had colorectal, endometrial or related cancers, or if you have had one of these cancers yourself and do not know whether the tumor was tested for mismatch repair. If a colonoscopy is overdue, or your doctor said the bowel preparation was not good enough to see clearly, arrange a repeat rather than waiting for the next scheduled one. Contact your care team promptly, without waiting for your next routine visit, if you notice blood in your stool, a change in bowel habits that lasts more than a few days, abnormal vaginal bleeding (such as bleeding between periods or after menopause), persistent bloating or abdominal pain, recurring urinary symptoms, or weight loss you cannot explain.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Lynch Syndrome II is like, what's helped you, or ask the community a question.